In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Edwards Lifesciences and Dexcom Join Forces in New Critical Care Growth Market

Executive Summary

A new market in hospital intensive care units has opened up for companies glucose monitoring technologies and it represents a double-digit growth opportunity both for companies with continuous glucose monitors and critical care franchises. As partners,, Edwards Lifesciences and Dexcom bring both the marketing and technological strengths to successfully compete in this new market.

You may also be interested in...



Tight Glycemic Control: Critical Care’s Balancing Act

Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving patient outcomes. Today, a small pack of companies is trying to finally deliver on the promise.

Tight Glycemic Control: Critical Care’s Balancing Act

Over a decade ago, the New England Journal of Medicine published a study identifying tight glycemic control in the intensive care unit as a critical step to improving outcomes. Today, GlySure and others are working on continuous glucose monitoring for the critical care environment to help deliver on that promise.

Recent Trends in Hemodynamic Monitoring

Growth in the hemodynamic monitoring market is being fueled by several factors, including the aging population and the increasing demand for less invasive and noninvasive technologies for measuring global parameters of oxygen delivery. While barriers to entry are high in the hemodynamic monitoring business, the prospect for future growth is significant.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC142271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel